What is the best non‑stimulant to add to a regimen of sertraline and aripiprazole (Abilify)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Best Non-Stimulant to Add to Sertraline and Abilify

You are already on aripiprazole (Abilify) with sertraline—this is the evidence-based augmentation strategy you should continue, as aripiprazole is the non-stimulant augmentation agent with the strongest evidence for treatment-resistant depression when added to SSRIs like sertraline.

Current Regimen Analysis

Your current combination of sertraline plus aripiprazole represents an established, evidence-based approach for treatment-resistant depression. The question appears to be asking about adding a third agent, but the evidence strongly suggests optimizing your current two-drug regimen first.

Evidence-Based Recommendations

Primary Strategy: Optimize Current Aripiprazole Dose

The optimal dose of aripiprazole for augmentation is 2-5 mg daily 1. The dose-response curve shows maximum efficacy between 2-5 mg, with no additional benefit at higher doses up to 20 mg, but potentially worse tolerability. If you're not at this dose range, adjustment should be the first step.

Why Aripiprazole + Sertraline is the Right Choice

  • Direct evidence for this combination: A randomized, double-blind trial specifically evaluated aripiprazole/sertraline combination versus placebo/sertraline in patients with inadequate response to sertraline 100 mg/day. The aripiprazole augmentation group showed significantly greater improvement (mean MADRS change -9.2 vs -7.2, p=0.0070) 2.

  • FDA compatibility: The Abilify label explicitly states "no dosage adjustment is necessary for sertraline when coadministered with ABILIFY" 3, confirming this is a safe, well-studied combination.

  • Guideline support: The 2023 American College of Physicians systematic review found that augmentation with aripiprazole showed higher remission rates (55.4%) compared to bupropion augmentation (34.0%, p=0.031) in treatment-resistant depression 4.

Alternative Non-Stimulant Options (If Changing Strategy)

If you must consider a different non-stimulant augmentation agent:

1. Bupropion SR (150-300 mg daily)

  • The STAR*D trial showed similar efficacy between bupropion SR and aripiprazole augmentation 4
  • Key advantage: Lower discontinuation due to adverse events (12.5%) compared to buspirone (20.6%, p<0.001)
  • Caveat: Less effective than aripiprazole in head-to-head comparison (34.0% vs 55.4% remission) 4

2. Buspirone (20-60 mg daily)

  • STAR*D data showed similar efficacy to bupropion for augmentation 4
  • Major disadvantage: Higher discontinuation rate due to adverse events (20.6%)

3. Mirtazapine (15-45 mg daily)

  • Can be added to sertraline (augmentation strategy)
  • Evidence shows no difference between switching to mirtazapine versus augmenting with mirtazapine 4
  • Consideration: Significant sedation and weight gain potential

Clinical Algorithm

Step 1: Verify aripiprazole dose is 2-5 mg daily (optimal range per meta-analysis) 1

Step 2: Ensure adequate trial duration—the sertraline/aripiprazole combination trial showed significant benefit at 6 weeks 2

Step 3: If inadequate response after 6-8 weeks at optimal doses:

  • Consider switching strategies rather than adding a third agent
  • Options include switching to a different antidepressant or switching to cognitive behavioral therapy 4

Step 4: If tolerability issues with aripiprazole (akathisia occurred in 12.9% in trials) 2:

  • Switch augmentation agent to bupropion SR as next best option
  • Avoid buspirone due to higher discontinuation rates

Important Safety Considerations

  • Drug interactions: Sertraline does not affect aripiprazole levels 3, making this a pharmacokinetically stable combination
  • Monitoring: Watch for akathisia (most common side effect at 12.9%), weight gain (mean 1.3 kg in combination therapy), and sedation 2
  • Avoid: Adding benzodiazepines increases sedation and orthostatic hypotension risk with aripiprazole 3

Why Not Add a Third Agent

The evidence does not support routinely adding a third psychotropic medication. The 2023 ACP guidelines found that various augmentation strategies showed similar efficacy, suggesting that optimizing your current two-drug regimen or switching strategies (not adding) is the evidence-based approach 4.

Bottom line: You're already on the best non-stimulant augmentation strategy (aripiprazole + sertraline). Optimize the aripiprazole dose to 2-5 mg daily rather than adding another agent.

References

Related Questions

Is it safe to add aripiprazole (Abilify) to a regimen that already includes sertraline (Zoloft) and ondansetron (Zofran)?
After stopping sertraline and finding quetiapine ineffective, how should I start aripiprazole (Abilify) and mirtazapine for mood stabilization and insomnia?
Can aripiprazole be added as augmentation therapy for an adult patient with major depressive disorder who has not achieved adequate improvement after an adequate (≥6 weeks) trial of a therapeutic dose of an SSRI or SNRI?
What are the drug interactions and safety considerations when using sertraline (Zoloft), aripiprazole (Abilify), and hydroxyzine together?
What is the likely cause and recommended management for a patient on aripiprazole (Abilify) and sertraline (Zoloft) who reports a persistent sensation of ants crawling on the face without any visible insects?
What evaluation and driving restrictions are recommended for a patient who lost consciousness while driving and was involved in an accident?
How should I give a patient who was started on Lantus (insulin glargine) take‑home instructions for titrating the basal insulin dose at home?
In a 63‑year‑old non‑diabetic woman taking olmesartan 40 mg, cilnidipine 20 mg, moxonidine 0.4 mg, spironolactone 25 mg, and metoprolol extended‑release 12.5 mg (which cannot be increased because of serious bradycardia) with persistent blood pressure of 146‑150/70‑80 mmHg, what adjustments should be made to her antihypertensive regimen?
Is it appropriate to add Strattera (atomoxetine) for attention‑deficit/hyperactivity disorder to my current treatment with sertraline and aripiprazole, and how should it be dosed and monitored?
What is the frequency of various locations of colonic diverticula?
How should I adjust the antihypertensive therapy for a female hypertensive patient who developed recurrent hyponatremia, leading to discontinuation of chlorthalidone, while she is currently on olmesartan, cilnidipine, spironolactone, metoprolol, and moxonidine, with eGFR ≥45 mL/min/1.73 m² and serum potassium <5.0 mmol/L?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.